Suppr超能文献

含麻疹成分疫苗与 4 至 6 岁儿童热性惊厥。

Measles-containing vaccines and febrile seizures in children age 4 to 6 years.

机构信息

Kaiser Permanente Vaccine Study Center, Oakland, CA 94612, USA.

出版信息

Pediatrics. 2012 May;129(5):809-14. doi: 10.1542/peds.2011-3198. Epub 2012 Apr 2.

Abstract

BACKGROUND

In the United States, children receive 2 doses of measles-mumps-rubella vaccine (MMR) and varicella vaccine (V), the first between ages 1 to 2 years and the second between ages 4 to 6 years. Among 1- to 2-year-olds, the risk of febrile seizures 7 to 10 days after MMRV is double that after separate MMR + V. Whether MMRV or MMR + V affects risk for febrile seizure risk among 4- to 6-year-olds has not been reported.

METHODS

Among 4- to 6-year-old Vaccine Safety Datalink members, we identified seizures in the emergency department and hospital from 2000 to 2008 and outpatient visits for fever from 2006 to 2008 during days 7 to 10 and 0 to 42 after MMRV and MMR + V. Incorporating medical record reviews, we assessed seizure risk after MMRV and MMR + V.

RESULTS

From 2006 through 2008, 86 750 children received MMRV; from 2000 through 2008, 67 438 received same-day MMR + V. Seizures were rare throughout days 0 to 42 without peaking during days 7 to 10. There was 1 febrile seizure 7 to 10 days after MMRV and 0 after MMR + V. Febrile seizure risk was 1 per 86 750 MMRV doses (95% confidence interval, 1 per 3 426 441, 1 per 15 570) and 0 per 67 438 MMR + V doses (1 per 18 282).

CONCLUSIONS

This study provides reassurance that MMRV and MMR + V were not associated with increased risk of febrile seizures among 4- to 6-year-olds. We can rule out with 95% confidence a risk greater than 1 febrile seizure per 15 500 MMRV doses and 1 per 18 000 MMR + V doses.

摘要

背景

在美国,儿童接受两剂麻疹-腮腺炎-风疹疫苗(MMR)和水痘疫苗(V),第一剂在 1 至 2 岁之间,第二剂在 4 至 6 岁之间。在 1 至 2 岁的儿童中,MMRV 接种后 7 至 10 天发生热性惊厥的风险是单独接种 MMR+V 的两倍。MMRV 或 MMR+V 是否会影响 4 至 6 岁儿童发生热性惊厥的风险尚未报道。

方法

在 4 至 6 岁的疫苗安全数据链接成员中,我们确定了 2000 年至 2008 年在急诊室和医院发生的癫痫发作,以及 2006 年至 2008 年在 MMRV 和 MMR+V 接种后 7 至 10 天和 0 至 42 天的发热门诊就诊。通过结合病历审查,我们评估了 MMRV 和 MMR+V 接种后的癫痫发作风险。

结果

2006 年至 2008 年期间,86750 名儿童接种了 MMRV;2000 年至 2008 年期间,67438 名儿童接种了 MMR+V。在第 0 至 42 天期间,没有出现癫痫发作高峰,整个期间癫痫发作都很罕见。MMRV 接种后 7 至 10 天有 1 例热性惊厥,MMR+V 接种后无热性惊厥。MMRV 接种的每 86750 剂疫苗中,热性惊厥的风险为 1 例(95%置信区间,1 例/3426441 例,1 例/15570 例),MMR+V 接种的每 67438 剂疫苗中,热性惊厥的风险为 0 例(1 例/18282 例)。

结论

这项研究令人安心的是,MMRV 和 MMR+V 与 4 至 6 岁儿童热性惊厥风险的增加无关。我们可以有 95%的信心排除 MMRV 每 15500 剂疫苗和 MMR+V 每 18000 剂疫苗发生热性惊厥的风险大于 1 例的情况。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验